Skip to content

Japan Morning Surge-1 Study

The Effects of Controlling Morning Hypertension on Target Organ Damage With Adrenergic Blockers, Based on Self-Measured Morning Blood Pressure Readings

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00285519
Enrollment
600
Registered
2006-02-02
Start date
2003-08-31
Completion date
2005-08-31
Last updated
2006-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Morning hypertension

Brief summary

The purpose of this study is to examine whether strict blood pressure (BP) control by doxazosin using home BP monitoring, especially targeting the morning BP level, can reduce hypertensive target organ damage.

Detailed description

Morning blood pressure may play an important role in the pathogenesis of hypertensive target organ damage. Increased sympathetic nerve activity is reported to be one of the mechanisms of morning hypertension; however, there are no available data that show whether strict home blood pressure control, especially in the morning period, can reduce target organ damage.We will evaluate whether strict morning blood pressure control by sympathetic nervous system blockade using an alfa-blocker, doxazosin, and with the addition of a beta-blocker if needed, can reduce hypertensive target organ damage.

Interventions

DRUGDoxazosin (drug)

Sponsors

Japan Heart Foundation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
0 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Morning systolic blood pressure \>135 mmHg in a sitting position at home while on stable antihypertensive medication for at least 3 months

Exclusion criteria

* History of heart failure * Presence of orthostatic hypotension, dementia, malignancy and chronic inflammatory disease * Taking an alfa-blocker or beta-blocker * Atrial fibrillation or atrial flutter

Design outcomes

Primary

MeasureTime frame
brain natriuretic peptide and the urinary albumin excretion/creatinine ratio at 6 months

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026